Alzheimer's trials: CTAD 2026
The 19th Clinical Trials on Alzheimer's Disease conference (CTAD) runs Nov. 16–19, 2026, in Boston (source: CTAD, checked Nov. 3, 2026).
By Mongevity Desk · About us · Corrections
CTAD is the meeting where Alzheimer's drug and test trials are presented, often for the first time: anti-amyloid antibodies, pills for early disease, blood tests for diagnosis. It is a specialist meeting, but its results end up in the headlines and in the questions people bring to their doctor.
This page follows the conference before, during and after: what is being tested, what each trial found in scales that mean something for daily life, the FDA status of each drug and our A–E evidence grade.
If you are worried about your memory or caring for someone with Alzheimer's, a result at a meeting is not a treatment you can get tomorrow. We say clearly when something could reach patients in the U.S., and when it could not.
When and where
Nov. 16–19, 2026 · Boston. The conference runs through Nov. 19; results are posted as they are presented. CTAD
How to follow it
- The conference posts its program and the abstract of each trial on its official site.
- Drug companies often announce their own results the same day; we always go back to the trial registry and the abstract.
- We post each result here with its date and source, and then explain it in its own article.
What's on the program
- Phase 3 results from the POLARIS-AD trial (AR1001)
- Phase 2a proof-of-concept data on NTRX-07, which targets inflammation in the brain (neuroinflammation)
- Topline results from the phase 2b PRImus-AD trial (PRI-002) in early Alzheimer's
- A symposium on trontinemab and Brainshuttle technology
- A symposium on posdinemab and tau biology
- A symposium on neuroinflammation and the NLRP3 inflammasome
- A symposium on remote digital biomarkers for Alzheimer's trials
- The LEADER symposium: real-world data from several centers on lecanemab, three years after its approval
From the CTAD 2026 program on the official site, checked Nov. 3, 2026. Being on the program says nothing yet about whether a drug works; we will add each result, its grade and its FDA status when it is presented. Official page
5 words you'll hear
- Late-breaking trialA study whose results are ready so close to the meeting that it gets a special session. It is new, not necessarily better.
- Primary endpointThe one result the trial was designed to measure. If a trial misses it, other good-looking numbers count much less.
- Phase 3The last and largest stage of testing in people before a drug can be submitted to the FDA.
- Hazard ratioHow the risk in the treated group compares with the control group over time. 0.80 means about 20% lower risk, relative to the other group.
- Absolute riskHow many people out of 100 had the outcome in each group. A 20% relative drop can mean going from 5 in 100 to 4 in 100.
Studies we covered before the meeting
These are recent studies on the same topics, not results from the meeting. Meeting results will appear above, each with its time and source.
- AStrong: large randomized trials or meta-analyses in people, with hard outcomes.
- BGood: randomized trials in people with smaller samples, shorter follow-up or lab markers.
- CModerate: well-done observational studies in people.
- DLimited: small or early studies in people.
- EVery limited: studies in cells or animals only.
| Study | Topic | Evidence | Why this grade | Original paper | Date |
|---|---|---|---|---|---|
| Alzheimer's and dementia | |||||
| No questionnaire predicted dementia very well; the best score was fair | Brain | B | Systematic review and meta-analysis of cohort studies; only three of ten scores could be pooled and accuracy varied by age and follow-up. | Paper | Nov. 3, 2026 |
| Narrower vessels in the eye were linked to early behavior changes before dementia | Brain | C | Prospective study combining eye, brain and blood measures; modest size, one region and exploratory biology, with no effect sizes in the abstract. | Paper | Nov. 3, 2026 |
| Lecanemab for Alzheimer’s in real life: blood markers moved first, brain swelling was rare | Brain | C | Multicenter real-world cohort without a control group; modest size and exploratory biomarker analyses. | Paper | Nov. 3, 2026 |
| A face-name test spotted early decline, a dementia warning sign, as well as the MoCA | Brain | C | Small single-country diagnostic accuracy study with moderate accuracy for both tests; needs external validation. | Paper | Nov. 3, 2026 |
| Older adults with dementia who had yearly wellness visits got dementia drugs more often | Brain | C | Very large observational study with complete Medicare data; cannot rule out differences between people who attend visits, and measures prescriptions, not outcomes. | Paper | Nov. 3, 2026 |
| A huge genetic study found 48 new Alzheimer’s risk regions, pointing to immune cells | Brain | C | Very large multi-ancestry genetic association study; robust for discovery but doesn't establish mechanisms or change care, and uses proxy cases. | Paper | Nov. 3, 2026 |
| Caring for someone with dementia | |||||
| For dementia caregivers, combining several kinds of support eased burden best | Brain | B | Network meta-analysis of randomized trials with sensitivity analysis; modest effect and heterogeneous designs. | Paper | Nov. 3, 2026 |
| A phone app for dementia caregivers improved their quality of life in 8 weeks | Brain | C | Small randomized trial with 8 weeks of follow-up; unblinded, self-reported outcomes and a single setting. | Paper | Nov. 3, 2026 |
| Patients on lecanemab did better when their caregivers felt more positive about caring | Brain | C | Multicenter longitudinal study with careful statistics; observational, modest size and unclear direction of the link. | Paper | Nov. 3, 2026 |
| Exercise and the brain | |||||
| For mild memory problems, moderate exercise doses worked best for thinking skills | Brain | B | Network meta-analysis of randomized trials; low to moderate certainty, heterogeneous trials and indirect comparisons. | Paper | Nov. 3, 2026 |
| In midlife women, regular exercise went with faster thinking, especially strength training | Brain | C | Small cross-sectional study; can't establish cause and may be confounded by other differences between exercisers and non-exercisers. | Paper | Nov. 3, 2026 |
| Exercise was linked to fewer pneumonia deaths in people with dementia | Brain | C | Very large nationwide registry; observational, activity self-reported once and possible reverse causation. | Paper | Nov. 3, 2026 |
| Food and the brain | |||||
| A daily cup’s worth of blueberries raised blood flow in one brain area of older adults | Brain | B | Double-blind randomized placebo-controlled trial, but small, three months long and measuring a brain-scan marker, not memory. | Paper | Nov. 3, 2026 |
| More ultraprocessed food was linked to more body fat and silent brain damage in midlife | Lifestyle | C | Large cross-sectional study with brain MRI, but can't establish temporality, and results depended on the food definition. | Paper | Nov. 3, 2026 |
| A strong sweet tooth in the diet was linked to dementia risk and older-looking biology | Aging | C | Prospective cohort with several aging markers; observational, confounding by other habits and preferences are not intake. | Paper | Nov. 3, 2026 |
Questions people ask
When is CTAD 2026?
The 19th Clinical Trials on Alzheimer's Disease conference (CTAD) runs Nov. 16–19, 2026, in Boston (source: CTAD, checked Nov. 3, 2026).
Where the data comes from
- CTAD: Clinical Trials on Alzheimer's Disease: The organizer's program and the abstract of each trial presented.
- ClinicalTrials.gov, National Institutes of Health: The official registry of clinical trials: phase, status, dates and results, filed by the researchers.
- PubMed, U.S. National Library of Medicine: Every study we grade links to the original journal article.
- U.S. Food and Drug Administration: press announcements: The FDA announces its own approvals, warnings and decisions.
Mongevity explains research. It does not give medical advice.